SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on February 9, 2023, covering events occurring on February 7, 2023. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The report details the outcomes of a special meeting of stockholders held to approve corporate governance and compensation matters.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate actions and voting results rather than financial performance metrics.
Material Changes and Voting Results
The primary material event was the approval of the BioSig Technologies, Inc. 2023 Long-Term Incentive Plan (the "Plan") by stockholders. The Board had previously approved the Plan on December 27, 2022, subject to this stockholder vote. The voting results were as follows:
- Total Votes Entitled: 54,577,305 (Common Stock) + 624,100 (Series C Convertible Preferred Stock).
- Votes For: 24,741,946
- Votes Against: 1,615,076
- Abstentions: 421,207
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors. The document references the definitive proxy statement filed on December 29, 2022, for further details regarding the Plan. The full text of the approved 2023 Long-Term Incentive Plan is included as Exhibit 10.1.
Investor Verification Checklist
- Verify the specific terms and share limits of the newly approved 2023 Long-Term Incentive Plan in Exhibit 10.1.
- Review the December 29, 2022, Special Meeting Proxy Statement for detailed rationale behind the Plan.
- Confirm the impact of the Series C Convertible Preferred Stock voting rights on future capital structure.
- Check subsequent filings for any immediate grants or issuances under the new Plan.